Navigation Links
SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
Date:3/11/2009

31, 2008, compared to $1.2 million in 2007. This decrease was primarily due to lower royalty income from Perrigo and termination of our relationship with Nutraceutix.

SCOLR has continued to make significant improvements to its operating efficiencies as compared to a year ago. For the year ended December 31, 2008, the Company's marketing and selling expenses decreased 28%, or $264,021, to $672,675, compared to $936,696 in 2007. General and administrative expenses decreased 4%, or $198,259, to $4.4 million for the year ended December 31, 2008, compared to $4.6 million in 2007.

Research and development expenses decreased 19%, or $1.5 million, to $6.3 million for the year ended December 31, 2008, compared to $7.8 million in 2007.

Net loss decreased 42%, or $4.5 million, to $6.1 million for the year ended December 31, 2008, compared to $10.6 million in 2007. This decrease was primarily due to the gain of $4.1 million from the termination of the lease of our corporate facility in 2008.

SCOLR Pharma had approximately $6.4 million in cash and cash equivalents, and $473,711 in restricted cash as of December 31, 2008. SCOLR anticipates that, based on its current operating plan, its existing cash and cash equivalents, together with expected royalties from third parties, will be sufficient to fund its operations until late 2009. SCOLR's current operating plan reflects reductions in personnel, marketing and other operating expenses implemented in 2008. SCOLR is actively managing its liquidity by limiting clinical and development expenses to its lead products and supporting existing alliances and collaborations. SCOLR has deferred all significant expenditures on new projects pending additional financing or partnership support. SCOLR is pursuing new partnerships as well as collaborations, and exploring other financing options that would provide the Company with additional funding for its operations. These
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
5. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
6. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
7. China Biopharma, Inc. Announces New Plan of Operation
8. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
9. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
10. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
11. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
(Date:11/21/2014)... NEW YORK and SAN DIEGO ... CYTX ), today announced that President and CEO Marc Hedrick ... 2014. DATE:   Thursday, December 4, 2014 ... LINK:     Click here or paste this URL into ... is recommended that investors pre-register to save time and receive ...
(Date:11/18/2014)... 2014 Cord Blood Registry® (CBR®) announces ... Annual World Stem Cell Summit, the largest global meeting of ... Stem Cell Summit will be held December 3-5 at the ... The World Stem Cell Summit ... and therapies, convening the most prominent figures in the field ...
(Date:11/18/2014)... New Orleans, LA (PRWEB) November 17, 2014 ... developer of build-to-order, open architecture blade-based and rackmount ... new NVIDIA® Tesla® K80 dual-GPU accelerator throughout its ... Utilizing a pair of the company‚Äôs latest proprietary ... up to eight discrete NVIDIA Tesla K80 dual-GPU ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
... Charter Business , a division of ... develop its partnership with Berbee Information Networks ... Pharmacy Cooperative (IPC) to Berbees data center in ... T1 lines between multiple Telco vendors, Charter hands off ...
... Metavante Corporation and First Data Corporation ... agreement that provides for the purchase of substantially all ... Metavante for approximately $610 million in cash. As the ... approximately $389 million and NYCE will become a Metavante ...
... exposures to agricultural and lawn care pesticides may cause ... noticed, according to a study conducted by ... being published in the May 2004 issue of ... Institute of Environmental Health Sciences, National Institutes of Health. ...
Cached Biology Technology:Charter and Berbee connect Pharmacy Cooperative 2Metavante and First Data to buy PIN-debit company NYCE 2Infertility linked to lawn chemicals by Marshfield Clinic researcher 2
(Date:11/4/2014)... LAKE CITY, Nov. 5, 2014 – University of Utah ... enzymes to help jet fuel produce electricity without needing ... be used to power portable electronics, off-grid power and ... online today in the American Chemical Society journal ... electricity through a chemical reaction between a fuel and ...
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Researchers at Case Western Reserve University have developed a ... to diseased areas within hours, as opposed to the ... , Using laboratory mice, drug delivery time from injection ... to mere hours. Using this as a model for ...
... of Canadian and Finnish scientists has identified a protein able ... involved in the recognition and the elimination of infectious agents. ... Immunology and Cancer (IRIC) at the Universit de Montral in ... in the latest edition of the journal Immunity ...
... at The University of Texas at Austin is part ... that should simplify the water desalination process, increasing access ... "If we make the desalination process more efficient with ... a gallon of water, which will expand the availability ...
Cached Biology News:Cancer drug delivery research at Case Western Reserve University cuts time from days to hours 2Cancer drug delivery research at Case Western Reserve University cuts time from days to hours 3Identification of protein able to stimulate production of T-cells 2New chlorine-tolerant, desalination membrane hopes to boost access to clean water 2
WTAP Antibody...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
... MSY2/YBOX2 ( Abpromise for all ... Synthetic peptide derived from within ... Human MSY2/YBOX2. (Note: the amino ... (Peptide available as ab27460 ...
Request Info...
Biology Products: